Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
Whey Protein wins 3 of 3 categories. Both are solid choices — the best pick depends on your specific goals.
Verdict
Mostly mechanism / observational
Top outcomes
Verdict
Likely helps
26 of 30 studies with measurable effects showed benefit.
Top outcomes
INVESTIGATIONAL — no approved consumer dose. In trials, once-daily oral orforglipron was titrated up to 36 mg (some phase-2 cohorts to 45 mg) with gradual dose escalation to limit GI side effects. Not for self-administration; only appropriate within a clinical trial or, if/when approved, under a prescribing clinician.
any
Oral tablet (investigational)
20-40g per serving
Post-workout (within 2 hours), Morning, Between meals
Whey Protein Isolate
Weeks to months
Months (titrated)
Throughout use
Especially during dose escalation
4-8 weeks
24-48 hours post-workout
Immediate
Within hours of consumption
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (ATTAIN-1).
N Engl J Med (2025) · Rct · n=3127
Phase-3 multinational double-blind RCT in 3,127 adults with obesity WITHOUT diabetes; once-daily oral orforglipron 6/12/36 mg vs placebo for 72 weeks
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes (ACHIEVE-1).
N Engl J Med (2025) · Rct · n=559
Phase-3 double-blind RCT in 559 adults with early type 2 diabetes managed by diet/exercise; once-daily oral orforglipron 3/12/36 mg vs placebo for 40 weeks
Orforglipron compared with dapagliflozin in adults with type 2 diabetes and inadequate glycaemic control with metformin (ACHIEVE-2): a multicentre, randomised, non-inferiority, open-label, phase 3 trial.
Lancet (2026) · Rct · n=962
Phase-3 non-inferiority RCT (n=962) in type 2 diabetes inadequately controlled on metformin; once-daily oral orforglipron 3/12/36 mg vs dapagliflozin 10 mg over 40 weeks
Comparative Efficacy of Different Protein Supplements on Muscle Mass, Strength, and Physical Indices of Sarcopenia among Community-Dwelling, Hospitalized or Institutionalized Older Adults Undergoing Resistance Training: A Network Meta-Analysis of Randomized Controlled Trials
Nutrients (2024) · Meta analysis · n=5272
Treatment effects for main outcomes were expressed as standard mean difference (SMD) with 95% confidence interval (CI).
Effects of Whey Protein, Leucine, and Vitamin D Supplementation in Patients with Sarcopenia: A Systematic Review and Meta-Analysis
Nutrients (2023) · Meta analysis · n=637
However, appendicular muscle mass significantly improved in the experimental group compared to the control group.
A systematic review, meta-analysis and meta-regression of the effect of protein supplementation on resistance training-induced gains in muscle mass and strength
British Journal of Sports Medicine (2018) · Meta analysis · n=1863
Protein supplementation increases muscle mass gains
Based on multiple meta-analyses with >3000 participants. Effects require concurrent resistance training. Benefits plateau around 30-40g per serving. Isolate forms may reduce digestive issues.
AI-estimated from published studies. Interpret as directional guidance.
Whey Protein has a higher evidence score (9/10 vs 5.5/10) and wins in 3 of 3 categories.
No known interactions between Orforglipron and Whey Protein have been documented in our database. However, always consult a healthcare provider before combining supplements.